Report of an International Psychogeriatric Association Special Meeting Work Group; Under the Cosponsorship of Alzheimer's Disease International, the European Federation of Neurological Societies, the World Health Organization, and the World Psychiatric Association

Reisberg, Barry; Burns, Alistair; Brodaty, Henry; Eastwood, Robin; Rossor, Martin N.; Sartorius, Norman; Winblad, Bengt

doi:10.1017/s1041610297004675

Cited by 23 publications

(9 citation statements)

References 93 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Likewise, the finding that AD patients had comparatively normal scores on the FBI (a tool designed to tap into emotional dysregulation related to frontal lobe atrophy) is not surprising, considering the relative sparing of frontal lobes in AD [32] . Some have found emotional symptoms to be unrelated to the neuropathological burden of AD [63,64] .…”

Section: Discussionmentioning

confidence: 99%

Utility of Behavioral versus Cognitive Measures in Differentiating between Subtypes of Frontotemporal Lobar Degeneration and Alzheimer’s Disease

Heidler‐Gary

Gottesman²,

Newhart

et al. 2007

Dement Geriatr Cogn Disord

View full text Add to dashboard Cite

We hypothesized that a modified version of the Frontal Behavioral Inventory (FBI-mod), along with a few cognitive tests, would be clinically useful in distinguishing between clinically defined Alzheimer’s disease (AD) and subtypes of frontotemporal lobar degeneration (FTLD): frontotemporal dementia (dysexecutive type), progressive nonfluent aphasia, and semantic dementia. We studied 80 patients who were diagnosed with AD (n = 30) or FTLD (n = 50), on the basis of a comprehensive neuropsychological battery, imaging, neurological examination, and history. We found significant between-group differences on the FBI-mod, two subtests of the Rey Auditory Verbal Learning Test (verbal learning and delayed recall), and the Trail Making Test Part B (one measure of ‘executive functioning’). AD was characterized by relatively severe impairment in verbal learning, delayed recall, and executive functioning, with relatively normal scores on the FBI-mod. Frontotemporal dementia was characterized by relatively severe impairment on the FBI-mod and executive functioning in the absence of severe impairment in verbal learning and recall. Progressive nonfluent aphasia was characterized by severe impairment in executive functioning with relatively normal scores on verbal learning and recall and FBI-mod. Finally, semantic dementia was characterized by relatively severe deficits in delayed recall, but relatively normal performance on new learning, executive functioning, and on FBI-mod. Discriminant function analysis confirmed that the FBI-mod, in conjunction with the Rey Auditory Verbal Learning Test, and the Trail Making Test Part B categorized the majority of patients as subtypes of FTLD or AD in the same way as a full neuropsychological battery, neurological examination, complete history, and imaging. These tests may be useful for efficient clinical diagnosis, although progressive nonfluent aphasia and semantic dementia are likely to be best distinguished by language tests not included in standard neuropsychological test batteries.

show abstract

Section: Discussionmentioning

confidence: 99%

Utility of Behavioral versus Cognitive Measures in Differentiating between Subtypes of Frontotemporal Lobar Degeneration and Alzheimer’s Disease

Heidler‐Gary

Gottesman²,

Newhart

et al. 2007

Dement Geriatr Cogn Disord

View full text Add to dashboard Cite

show abstract

“…Today, only specialised clinical expert centres achieve a correct diagnosis of probable and possible AD with an accuracy of more than 80 % on the basis of the medical history, a neuropsychological examination, cognitive symptoms, imaging techniques and, concerning other forms of *Address correspondence to this author at Business Development, BioVisioN AG, Feodor-Lynen-Str. 5, D-30625 Hannover, Germany; Tel: +49 (511) 538896-37; Fax: +49 (511) 538896-66; E-mail: h.selle@peptidomics.de 1 Differential Peptide Display, Peptidomics and Spectromania are trademarks of BioVisioN AG dementia, exclusionary parameters [2]. However, at such an advanced state of the disease the neurodegenerative process has already caused a substantial loss of brain tissue, yet a definite diagnosis can be done only post mortem b y histological examination of brain tissue.…”

Section: Introductionmentioning

confidence: 99%

“…Although the measurement of tau protein and Aβ in combination and the determination of phosphorylated tau protein is quite useful in distinguishing AD from healthy controls and from other neurodegenerative disorders [6,7], respectively, there is still a substantial need for further improvement of AD diagnosis [2,4].…”

Section: Introductionmentioning

confidence: 99%

Identification of Novel Biomarker Candidates by Differential Peptidomics Analysis of Cerebrospinal Fluid in Alzheimers Disease

Selle¹,

Lamerz²,

Büerger³

et al. 2005

CCHTS

View full text Add to dashboard Cite

The objective of this work was the application of peptidomics technologies for the detection and identification of reliable and robust biomarkers for Alzheimer's disease (AD) contributing to facilitate and further improve the diagnosis of AD. Using a new method for the comprehensive and comparative profiling of peptides, the differential peptide display (DPD), 312 cerebrospinal fluid (CSF) samples from AD patients, cognitively unimpaired subjects and from patients suffering from other primary dementia disorders were analysed as four independent analytical sets. By combination with a cross validation procedure, candidates were selected from a total of more than 6,000 different peptide signals based on their discriminating power. Twelve candidates were identified using mass-spectrometric techniques as fragments of the possibly neuroprotective neuroendocrine protein VGF and another one as the complement factor C3 descendent C3f. The combination of peptide profiling and cross validation resulted in the detection of novel potential biomarkers with remarkable robustness and a close relation to AD pathophysiology.

show abstract

“…The American College of Radiology recommends functional imaging for cases that are difficult to diagnose [77]. More recent consensus statements concur that imaging techniques have an important role to play in the diagnosis and assessment of dementia and specifically AD [78][79][80][81][82]. In the UK, both English and Scottish guidelines recommend imaging, in particular SPECT, for the differential diagnosis of difficult cases [83,84].…”

Section: Guidelines and Consensus Statementsmentioning

confidence: 99%

Is there Still a Place for Perfusion SPECT in the Diagnosis of Dementia?

Ebmeier

2010

TONMEDJ

View full text Add to dashboard Cite

Abstract:Although research interest within functional imaging has moved towards applications of MRI, such as BOLD and perfusion imaging, there is a wealth of clinical experience in emission tomographic imaging techniques that make the use of these modalities relevant for the decades to come. This review touches upon the technical and practical issues that distinguish SPECT from PET, describes perfusion and metabolic changes observed in the dementias, compares the clinical utility of the two techniques, and reports data on clinical sensitivity and specificity, as well as diagnostic head-to head comparisons in dementia, and specifically Alzheimer's disease. While few centres have a genuine choice between PET and SPECT, either appears to be good enough to help with the differential diagnosis of dementia in difficult cases.

show abstract

Report of an International Psychogeriatric Association Special Meeting Work Group; Under the Cosponsorship of Alzheimer's Disease International, the European Federation of Neurological Societies, the World Health Organization, and the World Psychiatric Association

Cited by 23 publications

References 93 publications

Utility of Behavioral versus Cognitive Measures in Differentiating between Subtypes of Frontotemporal Lobar Degeneration and Alzheimer’s Disease

Utility of Behavioral versus Cognitive Measures in Differentiating between Subtypes of Frontotemporal Lobar Degeneration and Alzheimer’s Disease

Identification of Novel Biomarker Candidates by Differential Peptidomics Analysis of Cerebrospinal Fluid in Alzheimers Disease

Is there Still a Place for Perfusion SPECT in the Diagnosis of Dementia?

Contact Info

Product

Resources

About